0001850119 false 0001850119 2022-04-13 2022-04-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, DC 20549









Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 13, 2022




Century Therapeutics, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-40498   84-2040295
(State or other jurisdiction of
incorporation or organization)
  (Commission File Number)   (I.R.S. Employer
Identification No.)


3675 Market Street

Philadelphia, Pennsylvania

(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (267) 817-5790


Not Applicable

(Former name or former address, if changed since last report)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class   Trading Symbol   Name of Exchange on Which Registered
Common Stock, par value $0.0001 per share   IPSC   Nasdaq Global Select Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨






Item 8.01 Other Events


On April 13, 2022, Century Therapeutics, Inc. (the “Company”) updated information reflected in a slide presentation, which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.


Item 9.01 Financial Statements and Exhibits


(d) Exhibits


99.1   Investor Presentation of Century Therapeutics, Inc., dated April 13, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By: /s/ Osvaldo Flores, Ph.D.
  Name: Osvaldo Flores, Ph.D.
  Title: President and Chief Executive Officer

Date: April 13, 2022





Exhibit 99.1





2 2 FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements within the meaning of, and made pursuant to the safe harbour provisions of , The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current c ond itions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market oppo rtu nity, competitive position and potential growth opportunities are forward - looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward - looking statements . In some cases, you can identify forward - looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “projec t,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward - looking statements in this presentation are only predictio ns. We have based these forward - looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financ ial condition and results of operations. These forward - looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of w hic h cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through devel opm ent activities, preclinical studies, and clinical trials; our reliance on the maintenance on certain key collaborative relationships for the manufacturing and development of our product candidates; the t imi ng, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID - 19 pandemic on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as thir d - p arty suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent fi lings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward - looking statements as predictions of future events. The events and circumstanc es reflected in our forward - looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward - looking statements. Moreover, we operat e in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may fa ce. Except as required by applicable law, we do not plan to publicly update or revise any forward - looking statements contained herein, whether as a result of any new information, future events, cha nged circumstances or otherwise.



3 3 Future Vision Century is developing transformative allogeneic cell therapies Establish franchises in B cell malignancies, GBM, solid tumor indications World - class cell engineering capabilities Develop best - in - class iPSC - derived iNK and iT cell platforms Financial strength maintained by platform synergies, efficiencies



4 4 Multiple gene edits (KO/KI) Product Candidate iPSC bank Sequential Precision Engineering Manufacturing PRECISION CRISPR MAD7 GENE EDITING OF I PSC CELLS UNLOCKS TRANSFORMATIONAL POTENTIAL Engineered iPSC Master Cell Bank Differentiation • Precise gene editing (MAD 7) enables engineering of candidates with synthetic functionalities • Quality control by ensuring genomic integrity is maintained • Clonal selection of MCB for homogenous products, scalable process Successive selection steps



5 5 ALLO - EVASION TM 1.0 DESIGNED TO OVERCOME THREE MAJOR PATHWAYS OF HOST VS GRAFT REJECTION b 2M KO (HLA - I) HLA - E KI CIITA KO (HLA - II) CD8 + T Cell CD4 + T Cell NK cell Deletion of β 2M, a protein required to express HLA - I on the cell surface prevents recognition by CD8 T cells Knock out of CIITA eliminates HLA - II expression to escape elimination by CD4 T cells Knock - in of HLA - E prevents killing by NK cells Core edits



6 6 CENTURY'S PROTEIN SCIENCES ENABLES ALL ASPECTS OF PROTEIN ENGINEERING OF OUR PRODUCT CANDIDATES Binder domains Transmembrane domain Signaling domains CAR Engineering • Enable fit - for - purpose CAR assembly • Multiple CAR formats for single - and multi - specific CARs • CAR Binder Discovery • Century Therapeutics’ proprietary VHH library • Partnerships with Distributed Bio and LakePharma • Signaling Domains • Signaling domains specifically optimized for iNK and iT cells Transgene Engineering • Allo - Evasion molecules • Safety switch • Cytokines • Chimeric proteins CRISPR - MAD7 Protein Engineering • Protein optimization, production, and characterization CAR Structure



7 7 STATE - OF - THE ART MANUFACTURING • cGMP manufacturing facility expected to be operational in 2022 • 53,000 ft 2 facility • Capable of production of NK and T cells, as well as other cell types DESIGNED TO POSITION CENTURY AS LEADER IN i PSC - BASED CELL THERAPY FOR CANCER Century’s multi - suite facility Branchburg, NJ Advantages of investing in manufacturing capabilities expertise • Fully integrated analytical and process development and manufacturing • More effectively implement process and product changes • Potentially accelerate clinical development of commercial product • Potential to achieve economies of scale



8 8 CELL ENGINEERING ENABLES RAPID PRODUCT ITERATION iNK 1.0 Fit for purpose tailored functionality iNK 3.0 Century’s Platform allows for potentially transformative product evolution illustrative Proposed Feature CNTY - 101 iNK 1.0 CNTY - 103 iNK 2.0 iNK 3.0 Illustrative Cytokine support Soluble IL - 15 mbIL - 15 mbIL - 15 Innate Activity + ++ (NKG2A KO) ++ (NKG2A KO) Undisclosed PET tracer Allo - Evasion HLA - 1 KO HLA - II KO HLA - E KI Undisclosed # of edits 6 6 12 KO 2 3 4 Site - specific KI 4 3 8



9 9 CENTURY’S FIRST GENERATION gd CAR - i T CELLS MULTIPLE BUILT - IN PATHWAYS FOR TUMOR KILLING PATHWAYS FOR POTENTIAL TUMOR KILLING 1. CAR - mediated killing 2. ADCC (Antibody - dependent cellular cytotoxicity) 3. Innate - receptor mediated killing (NKG2D, others) 1 2 3



10 10 γδ CAR - i T CELLS KILL LYMPHOMA CELLS THROUGH MULTIPLE ROUNDS OF KILLING WITHOUT REACHING EXHAUSTION Not for further distribution Serial Killing of CD19 + Lymphoma Cells by γδ CAR - iT cells 0 100 200 300 0 500000 1000000 1500000 Time Elapsed (hours) L i v e t u m o r c e l l s ( f l u o r e s c e n c e ) CAR-iT CAR-T Serial Killing Assay Setup



11 11 CENTURY’S EMERGING FRANCHISES B cell malignancies Glioblastoma Solid tumors • CNTY - 101 : Lead product candidate, CD19 targeted CAR - iNK • CNTY - 102 : First gd iT candidate, multi - specific (CD19 + CD79b) CAR - iT • CNTY - 103 : Multi - specific (CD133+ EGFR) CAR iNK for recurrent GBM • Follow - on candidate Potentially f irst product candidate to enter the clinic with edits designed to avoid all major pathways of rejection CNTY - 102 provides optionality to address additional subtypes / use in combination Multi - tumor antigen targeting addresses heterogeneity in GBM tumor cells Exploring additional tumor antigens and TME modulation features • Future candidate expected to be announced 4Q 2022 Leverage gd iT platform to target challenging solid tumors



12 12 ELIPSE - 1: PHASE 1 STUDY DESIGN* • Explore 1 to 2 cycles up to 6 doses with single LD conditioning • Effect of Allo - Evasion on iNK persistence after multiple doses • IND expected mid - 2022 to advance CNTY - 101 into Phase 1 clinical trial CNTY - 101: NEXT GENERATION CD19 TARGETED PRODUCT CNTY - 101 HLA - I Knockout IL - 15 HLA - II Knockout CD19 CAR Allo - Evasion TM edits HLA - E HIGHLY DIFFERENTIATED PROFILE Safety Switch First cell product candidate with 6 gene edits introduced with CRISPR - HDR Day 1 Day ~35 LD Day 15 PET/CT Day 50 Subsequent dose(s) for patients with clinical benefit Objective to dose without additional LD ELiPSE - 1 Schedule B * Subject to FDA approval



13 13 CNTY - 103: FIRST PROGRAM IN CNS MALIGNANCIES UNIQUELY POSITIONED TO ADDRESS CHALLENGES OF GBM HLA - I Knockout HLA - II Knockout Multi - specific EGFR/CD133 CAR Allo - Ev asi on edits HLA - E IL - 15/R a (membrane - bound) Challenge Century’s Solution Trafficking Local delivery with Ommaya reservoir Heterogeneity Targeting EGFR / EGFRvIII and CD133 (functional marker of treatment - resistant GBM cells) Toxicity Potentially minimize risks like CRS with iNK Persistence Potential to dose as needed • Targeting EGFR+ GBMs: Provides better coverage intended to ensure maximum tumor clearance • Targeting CD133+ GBMs: Clears functionally relevant treatment - resistant tumor cells



14 MULTIPLE CAR DESIGNS AND SIGNALING DOMAINS WERE INVESTIGATED TO DEVELOP THE CD133 x EGFR CAR TMD CD28 CD3z HINGE CD133 & EGFR BINDING DOMAINS CNTY - 103 CAR CD133xEGFR 0 20 40 60 0.0 0.5 1.0 1.5 2.0 2.5 Time (hr) T u m o r c e l l f r e q u e n c y CD28+CD3Z - CAR 41BB+CD3Z - CAR DAP10+CD3Z - CAR GBM BT935 cells alone No CAR Control Comparison Of The Cytotoxic Activity Of Multiple CD133xEGFR CAR Constructs Engineered With Different Signaling Domains



15 15 Product iPSC Platform Targets Indications Expected IND Submission Discovery Preclinical Clinical Collaborator CNTY - 101 iNK CD19 B - Cell Malignancies Mid 2022 CNTY - 103 iNK CD133 + EGFR Glioblastoma 2023 CNTY - 102 iT CD19 + CD79b B - Cell Malignancies 2024 CNTY - 104 iNK/ iT Multi - specific Acute Myeloid Leukemia 2024 CNTY - 106 iNK/ iT Multi - specific Multiple Myeloma 2024 Hematologic Tumors Solid Tumors Product candidate pipeline across cell platforms and targets in solid and hematologic cancers PIPELINE



16 16 CENTURY THERAPEUTICS’ UNIQUE INVESTMENT OPPORTUNITY • Well capitalized with cash runway into 2025 • Financial strength maintained by operational synergies • Comprehensive end - to - end allogeneic platform • iPSC derived iNK and iT cells, world - class gene editing, protein engineering and manufacturing • CNTY - 101 IND submission on track for mid - 2022 • CD19 targeted cell product designed to avoid 3 pathways of host rejection • CNTY - 103 IND enabling activities to initiate in 2022 • Century’s first solid tumor candidate for GBM • Experienced partner on board to tackle challenging malignancies • Bristol - Myers Squibb brings expertise in oncology and hematology